Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Early Metastatic Breast Cancer Cells May Not Be Stem Cell-Like, After All

November 20, 2015 9:18 am | by Cynthia Fox, Science Editor | Articles | Comments

Metastatic breast cancer cells that spread to the lung do not tend to be stem cells, a.k.a. cells undergoing the epithelial-mesenchymal (EMT) transition, says a new study in Nature. The finding contradicts the commonly held belief that stem-like EMT cancer cells are the main cells that metastasize. Read more...


WuXi, Lilly Team up To Develop Novel Small Molecule in China

November 20, 2015 8:15 am | News | Comments

The potential medicine aims to reduce cardiovascular events in patients with elevated LDL cholesterol and triglycerides at high risk of cardiovascular events. Read more...


Intelligent Gel Attacks Cancer

November 20, 2015 8:00 am | by University of Montreal | News | Comments

One form of immunotherapy involves treating cancer patients with anti-cancer immune cells. Read more...


Nepal Facing Medicine Shortages Due to Fuel Crisis, Blockade

November 20, 2015 7:45 am | by Binaj Gurubachrya, Associated Press | News | Comments

Shortages of life-saving medicine because of political protests in Nepal that have blocked key roads could lead to a crisis. Read more...


Mylan Launches Generic Adderall Tablets

November 20, 2015 7:30 am | News | Comments

They are the generic version of Teva's Adderall Tablets. Read more...


Dupilumab to Drive Global Atopic Dermatitis Treatment Market to $7.3B by 2024

November 20, 2015 7:15 am | by Abhilok Garg, Ph.D., Immunology Analyst, GlobalData | News | Comments

The off-label use of Novartis’ Xolair is also expected to increase, albeit at a slower rate towards the end of the forecast period. Read more...


Seeking the Right Prescription in Antibiotic Resistance Fight

November 20, 2015 7:00 am | by University of Oxford | News | Comments

Sixteen studies have been funded as part of a call for more research into drug resistant infections. Read more...


The Lure of Rare Disease Drugs

November 19, 2015 11:39 am | by Stephanie Guzowski, Editor | Articles | Comments

While rare diseases were historically passed over by pharmaceutical companies in favor of those with larger patient populations, such as cardiac disease and diabetes, today the story reads differently. Sales of orphan drugs are expected to grow at an annual rate of nearly 11 percent per year to about $176 billion in 2020, compared with 4 percent for drugs treating larger populations. Read more...


A 3-D Printing Revolution

November 19, 2015 11:31 am | by Drug Discovery & Development | Videos | Comments

In this one-minute video series, Drug Discovery & Development is highlighting the latest headlines and trends happening within the industry.


FDA Approves Nasal Spray Opioid Overdose Antidote

November 19, 2015 10:37 am | by Ryan Bushey, Associate Editor | News | Comments

Naloxone has been around for 40 years, but it has primarily been available as an FDA-approved injection. Read more...


AMA Calls for Ban of Drug Advertising, as Part of Affordability Initiative

November 19, 2015 10:36 am | by Seth Augenstein, Digital Reporter | News | Comments

Drug costs have skyrocketed in the last year-plus, causing outrage and fueling debates on both sides of the political aisle. The American Medical Association has taken the unprecedented step of calling for a ban to drug advertising direct to consumers, as part of a plan to bring down drug costs. Read more...


Lilly, Merck Expand Immuno-oncology Collaboration with Phase 3 NSCLC Trial

November 19, 2015 9:57 am | News | Comments

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase 3 study in first-line nonsquamous non-small cell lung cancer (NSCLC). Read more...


Thermo Fisher Signs Development Agreement for NGS-Based Companion Diagnostic

November 19, 2015 9:30 am | News | Comments

Thermo Fisher Scientific, the world leader in serving science, has entered into a long-term agreement with Novartis and Pfizer to develop and commercialize a multi-marker, universal next-generation sequencing (NGS) oncology test that will serve as a companion diagnostic (CDx) for non-small cell lung cancer (NSCLC) across multiple drug development programs. Read more...


‘Liquid Biopsy’ Could Offer Early Cancer Diagnoses of the Future

November 19, 2015 8:32 am | by Seth Augenstein, Digital Reporter | News | Comments

Cancer starts its assault quietly, and can go unnoticed until after it’s already conquered the body. Elaborate tests, scans and biopsies mean that constant monitoring of all the organs where it may start is not an option. But “liquid biopsies” could pick up a chemical trail in small blood samples, potentially offering the way to screen for any tumor in the future, according to findings by a team of scientists in Sweden.


Global Task Force Tackles Problem of Untreatable Cancers, Disease Relapse

November 19, 2015 8:00 am | by Saarland University | News | Comments

Many cancer therapies are highly toxic, and even when they appear to work, a significant percentage of patients will experience a relapse after only a few months. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.